Replies to post #25260 on The Rising Influence of Rising Affluence

[DewDiligence]

ZBH’s 2022 guidance assumes the fading of Omicron will fairly quickly be followed by a peak of yet another COVID variant. No other company I’m following has such a scenario as its base case, AFAIK.

Does any other public company have such a base-case scenario? If so, who? TIA

[DewDiligence]

ZBH 1Q22 results—2022 guidance:

https://investor.zimmerbiomet.com/news-and-events/news/2022/05-03-2022-113116507

1Q22 sales were +7% YoY in constant currency. 1Q22 non-GAAP EPS was $1.61, excluding the from the ZIMV segment during Jan and Feb, prior to the 3/1/22 spin-off. This compares to $1.71 non-GAAP EPS in 1Q21 (which included the ZIMV segment).

Elective-procedure recovery was stronger than the company expected. In Mar 2022 (but not Jan and Feb), procedure volume was higher than 2019 (pre-pandemic) levels.

2022 non-GAAP EPS guidance was raised and tightened to $6.65-$6.85 (from the prior range of $6.40-6.80).